AQST Q4 2022 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AQSTAquestive Therapeutics, Inc.

$431M

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$11M-3.6% YoY

Gross Profit

$5M50.3% margin

Operating Income

-$11M-100.3% margin

Net Income

-$12M-115.6% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

-6.8%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

$8M

Stock-Based Comp.

$714,000

Balance Sheet

Total Assets

$57M

Total Liabilities

$176M

Stockholders' Equity

-$119M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$11M	-3.6%
Gross Profit	$5M	$8M	-30.3%
Operating Income	-$11M	-$12M	+8.2%
Net Income	-$12M	-$29M	+57.3%

Revenue Segments

Manufacture and Supply Revenue

$9M84%

License and Royalty Revenue

$917,0009%

Proprietary Product Sales

$589,0006%

Co-Development and Research Fees

$254,0002%

Geographic Segments

UNITED STATES

$9M80%

Non-US

$2M20%